The board of directors of The United Laboratories International Holdings Limited announced that sodium hyaluronate eye drops (Specification: 0.1% (0.4ml: 0.4mg)) applied by Zhuhai United Laboratories Co. Ltd., Zhongshan Branch, a wholly-owned subsidiary of the Company, has been approved for marketing by China National Medical Products Administration, and is deemed to have passed the consistency evaluation of quality and efficacy for generic drugs. Sodium hyaluronate eye drops are indicated for xerophthalmia and it can relieve dry eye symptoms. Except for the specification difference from the marketed sodium hyaluronate eye drops (Specification: 5ml: 5mg; 7ml: 7mg) of the Company, this approved product is an OTC drug and is packaged in single dose (i.e. disposable eye drops) without preservatives, which is non-cross-infectious, portable and economical.

The approval further enriches the Company's ophthalmic product pipeline and helps to enhance the Company's market competitiveness in the field of drugs for the treatment of xerophthalmia. The Company will continue to focus on the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater benefits for the Company and its shareholders.